BRAF and central nervous system cancer: Cases presenting H3K27 alterations that are either “not-so-diffuse”, “not-so-midline” or “not-so-glioma” tumors should be thoroughly examined from a molecular point of view (DNA and RNA NGS, and methylation if possible) in search of additional alterations (e.g., BRAF V600 mutations); furthermore, in such cases, a centralized pathological revision or second opinion is always needed before attributing a definitive category to the tumor.